Related Experiment Video
Updated: Jun 27, 2026
09:08
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
Published on: October 14, 2021
Pathobiology and molecular profiling of peripheral T-cell lymphomas
Laurence de Leval1, Philippe Gaulard
1Pathology Department, University of Liège, CHU Sart Tilman, Liège, Belgium. L.deLeval@ulg.ac.be
Hematology. American Society of Hematology. Education Program
|December 17, 2008
Summary
Peripheral T-cell lymphomas (PTCLs) are aggressive rare cancers. Molecular profiling reveals distinct subtypes like Angioimmunoblastic T-cell lymphoma and Anaplastic Large Cell Lymphoma, offering new therapeutic insights.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Peripheral T-cell lymphomas (PTCLs) are a diverse group of aggressive rare cancers.
- Recent molecular profiling and clinico-pathological analyses have advanced understanding of nodal PTCL pathobiology.
- The specific molecular drivers for most PTCL entities remain largely unknown.
Purpose of the Study:
- To elucidate the molecular underpinnings of various PTCL subtypes.
- To identify novel biomarkers for therapeutic targeting.
- To differentiate distinct molecular subgroups within PTCL categories.
Main Methods:
- Molecular profiling studies.
- Clinico-pathological analyses.
- Gene expression profiling.
Main Results:
- Angioimmunoblastic T-cell lymphoma (AITL) involves CD4+ CXCL13+ cells, sharing features with follicular helper T cells, potentially explaining immune dysfunction.
- Anaplastic Large Cell Lymphoma (ALCL) is categorized into ALK+ (good prognosis, cytotoxic phenotype) and ALK- (distinct molecular features).
- PTCL, not otherwise specified (PTCL, NOS), the most common category, exhibits significant molecular heterogeneity, with gene expression profiling identifying potential therapeutic biomarkers and distinct subgroups.
Conclusions:
- PTCLs, despite rarity, present significant heterogeneity at the molecular level.
- Understanding the distinct molecular features of AITL, ALK+ ALCL, ALK- ALCL, and PTCL, NOS is crucial for accurate diagnosis and treatment.
- Novel biomarkers identified through gene expression profiling hold promise for future therapeutic strategies in PTCLs.
